Zollinger‑Ellison‑Associated Hyperparathyroidism: A Comprehensive Medical Guide
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by gastrin‑producing neuroendocrine tumors (gastrinomas) that lead to excessive stomach acid secretion. When ZES occurs as part of the hereditary syndrome multiple endocrine neoplasia type 1 (MEN‑1), patients often develop hyperparathyroidism in addition to the gastrinoma. This combined condition is frequently referred to as “Zollinger‑Ellison‑associated hyperparathyroidism.”
- Who it affects: Primarily adults aged 30‑60, with a slight male predominance in sporadic ZES and an equal sex distribution in MEN‑1‑related cases.
- Prevalence: ZES occurs in about 1 – 3 per million people worldwide. MEN‑1 is found in ~1 per 30,000 individuals, and hyperparathyroidism is the most common manifestation of MEN‑1, present in ~90 % of affected patients [1].
Because both conditions share a genetic background (MEN‑1 gene mutations), they often present together, and the clinical picture can be complex. Understanding the overlap is essential for timely diagnosis and appropriate treatment.
Symptoms
Symptoms arise from two linked sources: excess gastric acid (ZES) and elevated calcium levels (hyperparathyroidism). The following list groups them by organ system for clarity.
Gastro‑intestinal (Zollinger‑Ellison)
- Recurrent Peptic Ulcers: Multiple ulcers throughout the stomach and duodenum, often resistant to standard therapy.
- Abdominal Pain: Burning or gnawing pain that may improve after meals (likely ulcer‑related) or worsen (acid reflux).
- Diarrhea or Steatorrhea: Acid inactivates pancreatic enzymes, leading to fat malabsorption.
- Heartburn & GERD: Persistent reflux symptoms due to high acid load.
- Nausea & Vomiting: Especially after large meals.
Endocrine (Hyperparathyroidism)
- Hypercalcemia‑related fatigue & weakness
- Kidney stones: Calcium oxalate stones produce flank pain and hematuria.
- Psychiatric changes: Irritability, depression, “brain fog.”
- Bone pain & fractures: Due to increased bone resorption (osteitis fibrosa cystica).
- Abdominal “stones, bones, groans, thrones, and psychiatric overtones” – classic mnemonic for hyperparathyroidism.
- Polyuria & polydipsia: Excess calcium interferes with renal concentrating ability.
Combined/Other Symptoms
- Weight loss (malabsorption + hypermetabolism)
- Reduced appetite
- Bone density loss detectable on DEXA scans
Causes and Risk Factors
Understanding the underlying biology helps to identify individuals at risk.
Genetic Basis
- MEN‑1 Gene Mutation: Autosomal‑dominant mutation in the tumor suppressor gene MEN1 leads to proliferation of endocrine cells in the parathyroid, pancreas, and pituitary. Approximately 70‑80 % of MEN‑1 patients develop gastrinomas, and >90 % develop hyperparathyroidism [2].
Non‑genetic (Sporadic) Forms
- Isolated gastrinomas (10‑20 % of ZES) without MEN‑1 can still cause hyperparathyroidism due to concurrent primary hyperparathyroidism (often unrelated).
Risk Factors
- Family history of MEN‑1 or related endocrine tumors.
- Known MEN‑1 mutation carriers (screened via genetic testing).
- Age 30‑60 (most cases diagnosed in this window).
- Smoking and high‑fat diets have been linked to more aggressive gastrinomas, though data are limited.
Diagnosis
Because the two conditions overlap, a systematic approach is required.
Initial Laboratory Evaluation
- Serum Gastrin Level: Fasting gastrin >1000 pg/mL (or >10× upper limit) strongly suggests ZES, especially if the patient is off proton‑pump inhibitors (PPIs) for ≥1 week.
- Serum Calcium & Parathyroid Hormone (PTH): Elevated calcium with inappropriately high PTH confirms primary hyperparathyroidism.
- 24‑Hour Urinary Calcium: Helps differentiate familial hypocalciuric hypercalcemia from hyperparathyroidism.
- Vitamin D Levels: Deficiency can mask hypercalcemia and should be repleted before surgery.
Imaging Studies
- Endoscopic Ultrasound (EUS): Sensitive for detecting small pancreatic or duodenal gastrinomas.
- Somatostatin Receptor Scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT: Localizes neuroendocrine tumors with >90 % sensitivity.
- 4‑D CT (Dynamic Contrast‑enhanced CT): Provides anatomic detail for surgical planning.
- Sestamibi Scan or 4‑D Parathyroid Imaging: Identifies hyperfunctioning parathyroid tissue.
- Bone Density (DEXA): Baseline assessment for osteopenia/osteoporosis.
Genetic Testing
All patients with ZES under 50 years old, or any with a family history of endocrine tumors, should be offered MEN1 mutation analysis. A positive result guides surveillance of other MEN‑1 manifestations.
Diagnostic Criteria Summary
| Finding | Cut‑off/Interpretation |
|---|---|
| Fasting Gastrin | >1000 pg/mL (or >10× ULN) after stopping PPIs |
| Serum Calcium | >10.5 mg/dL (2.6 mmol/L) with high/normal PTH |
| Sestamibi Scan | Focal uptake consistent with parathyroid adenoma |
| Genetic Test | Pathogenic MEN1 mutation |
Treatment Options
Management must address both acid hypersecretion and hyperparathyroidism, often simultaneously.
Medical Therapy for ZES
- High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 40‑80 mg daily or equivalent; most effective at controlling acid output.
- H2‑Blockers: May be added for breakthrough symptoms, but PPIs remain first‑line.
- Somatostatin Analogs (Octreotide, Lanreotide): Reduce gastrin secretion, useful when tumors are unresectable or metastasized.
- Chemotherapy/Radiopharmaceuticals: For metastatic gastrinomas, options include streptozocin‑based regimens or peptide‑receptor radionuclide therapy (PRRT).
Surgical Management of Gastrinomas
- Localized Tumors: Enucleation or segmental resection of the duodenum/pancreas when feasible.
- Multifocal Disease (common in MEN‑1): Pancreaticoduodenectomy (Whipple) or distal pancreatectomy may be required; surgery is individualized based on tumor burden and patient comorbidities.
Treatment of Primary Hyperparathyroidism
- Parathyroidectomy: Curative in >95 % of sporadic cases; for MEN‑1, a “subtotal” (3.5 glands) or “total” (all four glands with autotransplantation) approach is typical.
- Calcimimetics (Cinacalcet): Useful for patients who are not surgical candidates; lowers calcium by increasing the sensitivity of the calcium‑sensing receptor.
- Bisphosphonates or Denosumab: Treat bone loss while awaiting definitive surgery.
Lifestyle & Supportive Measures
- Low‑fat, low‑oxalate diet to reduce kidney‑stone risk.
- Maintain adequate hydration (≥2‑3 L/day) to flush calcium.
- Calcium and vitamin D supplementation after parathyroid surgery (under physician guidance).
- Regular follow‑up labs: fasting gastrin, calcium, PTH, vitamin D every 3‑6 months.
Living with Zollinger‑Ellison‑Associated Hyperparathyroidism
Chronic illness management focuses on adherence to medication, monitoring, and lifestyle modifications.
Daily Management Tips
- Medication Timing: Take PPIs 30 minutes before breakfast; if using a calcimimetic, follow the exact schedule prescribed.
- Meal Planning: Small, frequent meals that are low in fat and high in protein help limit acid spikes and improve nutrient absorption.
- Hydration Strategy: Carry a water bottle; aim for a urine output of at least 1.5 L/day to prevent stones.
- Bone Health: Weight‑bearing exercise (walking, resistance training) 3‑4 times per week; schedule DEXA scans every 1‑2 years.
- Monitor Symptoms: Keep a log of abdominal pain, bowel habits, and any neurological changes; share with your endocrinologist.
- Support Networks: Join MEN‑1 or neuroendocrine tumor support groups (e.g., NACB – Neuroendocrine Cancer Awareness). Peer support improves adherence and mental health.
Follow‑up Schedule
| Visit Type | Frequency | Key Tests |
|---|---|---|
| Endocrinology | Every 3–6 months | Serum calcium, PTH, fasting gastrin, vitamin D |
| Gastroenterology | Every 6–12 months | Endoscopy (if ulcer symptoms), imaging if tumor growth suspected |
| Surgeon (if post‑op) | 1 month, 6 months, then annually | Calcium, PTH, imaging for recurrence |
Prevention
Because the condition has a strong genetic component, true primary prevention is limited, but risk can be mitigated.
- Genetic Counseling: Families with a known MEN1 mutation should undergo counseling and consider prenatal or pre‑implantation genetic testing if desired.
- Screening: At‑risk relatives (first‑degree) should have baseline calcium, PTH, and fasting gastrin levels starting at age 10‑15, and repeat every 1‑2 years.
- Lifestyle: Avoid smoking and excessive alcohol, which may accelerate tumor growth.
- Medication Review: Long‑term PPI use can mask gastrin levels; discuss with your physician the timing of medication holidays for accurate testing.
Complications
If untreated or poorly controlled, the combined disease can lead to serious health issues.
- Peptic Ulcer Perforation & Bleeding: Can cause peritonitis, require emergent surgery.
- Gastro‑intestinal Obstruction: From tumor mass effect or ulcer scarring.
- Kidney Stones & Chronic Kidney Disease: Recurrent stones can damage renal parenchyma.
- Severe Hypercalcemia (Calcium >14 mg/dL): Leads to arrhythmias, pancreatitis, neuro‑cognitive decline.
- Osteoporosis & Pathological Fractures: Result from chronic bone resorption.
- Metastatic Gastrinoma: Approximately 20‑30 % of sporadic gastrinomas metastasize to liver or lymph nodes, reducing survival.
- MEN‑1 Associated Tumors: Pituitary adenomas, bronchial carcinoids, and adrenal lesions may develop, necessitating broader surveillance.
When to Seek Emergency Care
Immediate medical attention is required if you experience any of the following:
- Severe, sudden abdominal pain with rigidity or guarding (possible ulcer perforation).
- Profuse or persistent vomiting, especially if blood is present.
- Signs of a kidney stone episode: intense flank pain radiating to the groin, accompanied by blood in urine.
- Symptoms of hypercalcemic crisis: confusion, lethargy, rapid heartbeat, shortness of breath, or muscle weakness.
- Sudden onset of dizziness, fainting, or palpitations (possible cardiac arrhythmia from high calcium).
- Unexplained, severe bone pain or a fracture from a minor fall.
Call 911 or go to the nearest emergency department if any of these occur.
References
- Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. “Primary Hyperparathyroidism.” 2022. https://www.niddk.nih.gov
- Cleveland Clinic. “MEN1 (Multiple Endocrine Neoplasia Type 1).” 2024. https://my.clevelandclinic.org
- World Health Organization. “Neuroendocrine tumours.” WHO Classification of Tumours, 5th ed., 2023.
- Thakker RV, et al. “Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).” J Clin Endocrinol Metab. 2022;107(6):1905‑1924.
- Jain R, et al. “Management of Zollinger‑Ellison syndrome in MEN‑1 patients.” Ann Surg Oncology. 2021;28(9):5234‑5242.